ArticleInfection2026
Pediatric malaria in a non-endemic European setting: clinical patterns, laboratory markers, and the ambiguous role of immunity.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePediatric malaria in non-endemic regions poses diagnostic and management challenges, particularly in the context of migration and international travel. This study aimed to characterize clinical, laboratory, and epidemiological features of pediatric malaria in a European non-endemic setting and to evaluate whether presumed immune status influences disease severity.
methodsWe conducted a retrospective study of children diagnosed with malaria at a tertiary center in Milan, Italy (2004-2024). Patients were stratified by presumed immune status into Non-Immune (NI) (Italian-born) and Presumed-Immune (PI) (foreign-born or frequent travelers to endemic areas). Differences between groups were analyzed using the Mann-Whitney U and Fisher's exact tests. Associations between laboratory markers (serum sodium, C-reactive protein [CRP], and platelet count) and clinical outcomes (length of hospital stay and fever duration) were evaluated using Spearman's rank correlation (ρ).
resultsSeventy-four cases were included (59% male; median age 9.0 years). Patients were stratified into Non-Immune (NI, 47.3%) and Presumed-Immune (PI, 52.7%) groups; the PI group was significantly older (p < 0.001). P. falciparum (62.2%) and P. vivax (27%) were the main species. Severe malaria (WHO 2015 criteria) occurred in 23% of patients, with no significant difference between NI and PI groups (p = 0.783). Spearman's analysis showed that serum sodium levels were inversely associated with length of hospital stay (ρ = - 0.284, p = 0.020), while CRP levels correlated positively with fever duration (ρ = 0.256, p = 0.033) and strongly negatively with platelet counts (ρ = - 0.585, p < 0.001). A significant therapeutic shift occurred post-2015, with intravenous artesunate replacing quinine as the gold standard treatment for severe malaria.
conclusionPediatric malaria severity and biochemical profiles appeared largely independent of presumed immune status in non-endemic settings. Clinical outcomes were more closely associated with admission laboratory markers-particularly hyponatremia and elevated CRP levels-than with geographic proxies of immunity. The adoption of intravenous artesunate as first-line therapy after 2015 was associated with improved clinical management. These findings highlight the need for careful monitoring of all pediatric malaria cases, regardless of prior exposure, as traditional classifications based on presumed immunity may not reliably predict disease severity.
Indexed as
Identifiers
41935227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.